CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
治疗 AML 的抗 FLT3 CAR-T 细胞疗法开发最新进展
英文原题：Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML.
查看英文原题
Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
继抗CD19嵌合抗原受体（CAR）T细胞疗法在B细胞恶性肿瘤中取得成功后，CAR-T 细胞疗法正被开发用于其他恶性肿瘤，如急性髓系白血病（AML）。复发AML患者的治疗选择有限，而恶性T细胞中FMS样酪氨酸激酶3（FLT3）的上调目前不仅被作为预后因素进行研究，也被作为新治疗方案的靶点。在这篇综述中，我们概述并讨论了当前正在开发的抗FLT3 CAR-T 细胞的不同方法。总体而言，这些疗法在体外和体内均有效，但安全性特征仍需进一步研究。首批临床试验已经启动，学界目前正等待以CAR-T 细胞靶向FLT3这一方法的临床评估。
展开英文摘要原文
Following the success of the anti-CD19 chimeric antigen receptor (CAR) T-cell therapies against B-cell malignancies, the CAR T-cell approach is being developed towards other malignancies like acute myeloid leukemia (AML). Treatment options for relapsed AML patients are limited, and the upregulation of the FMS-like tyrosine kinase 3 (FLT3) in malignant T-cells is currently not only being investigated as a prognostic factor, but also as a target for new treatment options.
In this review, we provide an overview and discuss different approaches of current anti-FLT3 CAR T-cells under development. In general, these therapies are effective both in vitro and in vivo, however the safety profile still needs to be further investigated. The first clinical trials have been initiated, and the community now awaits clinical evaluation of the approach of targeting FLT3 with CAR T-cells.
论文信息
- 作者
- Pedersen MG、Møller BK、Bak RO
- 第一作者单位
- Department of Clinical Immunology, Aarhus University Hospital, 8200 Aarhus, Denmark.Denmark
- 通讯作者单位
- Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark.Denmark
- 文献类型
- 综述
- 期刊
- Biomedicines2022 Sep 30
- 原文标识
- PubMed 36289703 · DOI 10.3390/biomedicines10102441
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →